View in EDS PDF Full Text

Prognostic significance of CD20 expression in Adults B-cell acute lymphoblastic leukemia.

Saved in:
Bibliographic Details
Title: Prognostic significance of CD20 expression in Adults B-cell acute lymphoblastic leukemia.
Alternate Title: Importancia pronóstica de la expresión de CD20 en leucemia linfoblástica aguda de células B en adultos.
Authors: Adnan, Ban1 Bana87_2011@yahoo.com, Sahham, Alaadin2 dr.alaa1972@yahoo.com, Alwan, Alaa Fadhil3 ala_sh73@yahoo.com
Source: Revista Latinoamericana de Hipertensión. 2023, Vol. 18 Issue 4, p152-157. 6p.
Subjects: B cells, RITUXIMAB, LYMPHOBLASTIC leukemia, ACUTE leukemia, CD20 antigen, BONE marrow cells, ADULTS
Geographic Terms: IRAQ
Abstract (English): Introduction: Acute lymphoblastic leukemia is a lymphocyte malignancy characterized by clonal buildup of immature blood cells in the bone marrow that are halted in the lymphoblast stage of development. CD20 is expressed on both normal and malignant B-cell lineage cells at all stages of development except precursor and plasma cells in 40-60% of B-cell precursor ALL patients. The aim of study is to evaluate CD20-positive B-ALL patients and comparing post-induction complete remission, event-free survival, and overall survival between those who received rituximab and those who did not. Method: Retrospective, prospective single-center cohort research at Baghdad Hematology Teaching Centre, Medical Complex, Iraq. Forty-nine Iraqi B-ALL patients from January 2017 to August 2021 were studied. The laboratory teaching centre and participants gather data during their frequent trips to the hospital’s ward, day care unit, and consultation room. Results: At diagnosis, patients were (33.5±17.9) years old and 1.8:1 male to female. All patients had CD20 expression, with 48.98% diverse and 12.24% moderate. Significant connection. Rituximab-treated individuals survived 50% in the first year, 45% in the second, and 5% in the third. Overall survival is significantly different between patients who got rituximab with induction regimen and those who did not (P= 0.049). Male gender is associated with overall survival. WBC, age, Philadelphia chromosome positive, and expressions did not affect overall survival between the two groups. Rituximab did not affect event-free survival (P=0.2). Event-free survival (EFS=36 months) is significantly higher in R-hyper CVAD patients. Conclusion: Rituximab improved survival. Male gender affects survival. Rituximab did not improve event-free survival. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Introducción: La leucemia linfoblástica aguda es una neoplasia maligna de linfocitos caracterizada por la acumulación clonal de células sanguíneas inmaduras en la médula ósea que se detienen en la etapa de desarrollo de linfoblastos. CD20 se expresa en células de linaje de células B tanto normales como malignas en todas las etapas de desarrollo, excepto en células precursoras y plasmáticas en el 40-60 % de los pacientes con LLA de precursores de células B. El objetivo del estudio es evaluar a los pacientes con B-ALL positivos para CD20 y comparar la remisión completa posterior a la inducción, la supervivencia libre de eventos y la supervivencia general entre los que recibieron rituximab y los que no. Método: investigación retrospectiva prospectiva de cohorte de un solo centro en el Centro de Enseñanza de Hematología de Bagdad, Complejo Médico, Irak. Se estudiaron cuarenta y nueve pacientes iraquíes con B-ALL desde enero de 2017 hasta agosto de 2021. El centro de enseñanza del laboratorio y los participantes recopilan datos durante sus frecuentes viajes a la sala del hospital, la unidad de cuidado diurno y la sala de consulta. Resultados: Al momento del diagnóstico, los pacientes tenían (33,5±17,9) años y 1,8:1 de hombres a mujeres. Todos los pacientes tenían expresión de CD20, con un 48,98% diversa y un 12,24% moderada. Conexión significativa. Los individuos tratados con rituximab sobrevivieron un 50 % en el primer año, un 45 % en el segundo y un 5 % en el tercero. La supervivencia global es significativamente diferente entre los pacientes que recibieron rituximab con el régimen de inducción y los que no lo recibieron (p = 0,049). El sexo masculino se asocia con la supervivencia global. WBC, la edad, el cromosoma Filadelfia positivo y las expresiones no afectaron la supervivencia general entre los dos grupos. Rituximab no afectó la supervivencia libre de eventos (P = 0,2). La supervivencia libre de eventos (SSC = 36 meses) es significativamente mayor en los pacientes con R-hiper CVAD. Conclusión: Rituximab mejoró la supervivencia. El género masculino afecta la supervivencia. Rituximab no mejoró la supervivencia libre de eventos. [ABSTRACT FROM AUTHOR]
Copyright of Revista Latinoamericana de Hipertensión is the property of Revista Latinoamericana de Hipertension and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 171909372
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Prognostic significance of CD20 expression in Adults B-cell acute lymphoblastic leukemia.
– Name: TitleAlt
  Label: Alternate Title
  Group: TiAlt
  Data: Importancia pronóstica de la expresión de CD20 en leucemia linfoblástica aguda de células B en adultos.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Adnan%2C+Ban%22">Adnan, Ban</searchLink><relatesTo>1</relatesTo><i> Bana87_2011@yahoo.com</i><br /><searchLink fieldCode="AR" term="%22Sahham%2C+Alaadin%22">Sahham, Alaadin</searchLink><relatesTo>2</relatesTo><i> dr.alaa1972@yahoo.com</i><br /><searchLink fieldCode="AR" term="%22Alwan%2C+Alaa+Fadhil%22">Alwan, Alaa Fadhil</searchLink><relatesTo>3</relatesTo><i> ala_sh73@yahoo.com</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Revista+Latinoamericana+de+Hipertensión%22">Revista Latinoamericana de Hipertensión</searchLink>. 2023, Vol. 18 Issue 4, p152-157. 6p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22B+cells%22">B cells</searchLink><br /><searchLink fieldCode="DE" term="%22RITUXIMAB%22">RITUXIMAB</searchLink><br /><searchLink fieldCode="DE" term="%22LYMPHOBLASTIC+leukemia%22">LYMPHOBLASTIC leukemia</searchLink><br /><searchLink fieldCode="DE" term="%22ACUTE+leukemia%22">ACUTE leukemia</searchLink><br /><searchLink fieldCode="DE" term="%22CD20+antigen%22">CD20 antigen</searchLink><br /><searchLink fieldCode="DE" term="%22BONE+marrow+cells%22">BONE marrow cells</searchLink><br /><searchLink fieldCode="DE" term="%22ADULTS%22">ADULTS</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22IRAQ%22">IRAQ</searchLink>
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: Introduction: Acute lymphoblastic leukemia is a lymphocyte malignancy characterized by clonal buildup of immature blood cells in the bone marrow that are halted in the lymphoblast stage of development. CD20 is expressed on both normal and malignant B-cell lineage cells at all stages of development except precursor and plasma cells in 40-60% of B-cell precursor ALL patients. The aim of study is to evaluate CD20-positive B-ALL patients and comparing post-induction complete remission, event-free survival, and overall survival between those who received rituximab and those who did not. Method: Retrospective, prospective single-center cohort research at Baghdad Hematology Teaching Centre, Medical Complex, Iraq. Forty-nine Iraqi B-ALL patients from January 2017 to August 2021 were studied. The laboratory teaching centre and participants gather data during their frequent trips to the hospital’s ward, day care unit, and consultation room. Results: At diagnosis, patients were (33.5±17.9) years old and 1.8:1 male to female. All patients had CD20 expression, with 48.98% diverse and 12.24% moderate. Significant connection. Rituximab-treated individuals survived 50% in the first year, 45% in the second, and 5% in the third. Overall survival is significantly different between patients who got rituximab with induction regimen and those who did not (P= 0.049). Male gender is associated with overall survival. WBC, age, Philadelphia chromosome positive, and expressions did not affect overall survival between the two groups. Rituximab did not affect event-free survival (P=0.2). Event-free survival (EFS=36 months) is significantly higher in R-hyper CVAD patients. Conclusion: Rituximab improved survival. Male gender affects survival. Rituximab did not improve event-free survival. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: Introducción: La leucemia linfoblástica aguda es una neoplasia maligna de linfocitos caracterizada por la acumulación clonal de células sanguíneas inmaduras en la médula ósea que se detienen en la etapa de desarrollo de linfoblastos. CD20 se expresa en células de linaje de células B tanto normales como malignas en todas las etapas de desarrollo, excepto en células precursoras y plasmáticas en el 40-60 % de los pacientes con LLA de precursores de células B. El objetivo del estudio es evaluar a los pacientes con B-ALL positivos para CD20 y comparar la remisión completa posterior a la inducción, la supervivencia libre de eventos y la supervivencia general entre los que recibieron rituximab y los que no. Método: investigación retrospectiva prospectiva de cohorte de un solo centro en el Centro de Enseñanza de Hematología de Bagdad, Complejo Médico, Irak. Se estudiaron cuarenta y nueve pacientes iraquíes con B-ALL desde enero de 2017 hasta agosto de 2021. El centro de enseñanza del laboratorio y los participantes recopilan datos durante sus frecuentes viajes a la sala del hospital, la unidad de cuidado diurno y la sala de consulta. Resultados: Al momento del diagnóstico, los pacientes tenían (33,5±17,9) años y 1,8:1 de hombres a mujeres. Todos los pacientes tenían expresión de CD20, con un 48,98% diversa y un 12,24% moderada. Conexión significativa. Los individuos tratados con rituximab sobrevivieron un 50 % en el primer año, un 45 % en el segundo y un 5 % en el tercero. La supervivencia global es significativamente diferente entre los pacientes que recibieron rituximab con el régimen de inducción y los que no lo recibieron (p = 0,049). El sexo masculino se asocia con la supervivencia global. WBC, la edad, el cromosoma Filadelfia positivo y las expresiones no afectaron la supervivencia general entre los dos grupos. Rituximab no afectó la supervivencia libre de eventos (P = 0,2). La supervivencia libre de eventos (SSC = 36 meses) es significativamente mayor en los pacientes con R-hiper CVAD. Conclusión: Rituximab mejoró la supervivencia. El género masculino afecta la supervivencia. Rituximab no mejoró la supervivencia libre de eventos. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Revista Latinoamericana de Hipertensión is the property of Revista Latinoamericana de Hipertension and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=171909372
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.5281/zenodo.8225822
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 6
        StartPage: 152
    Subjects:
      – SubjectFull: B cells
        Type: general
      – SubjectFull: RITUXIMAB
        Type: general
      – SubjectFull: LYMPHOBLASTIC leukemia
        Type: general
      – SubjectFull: ACUTE leukemia
        Type: general
      – SubjectFull: CD20 antigen
        Type: general
      – SubjectFull: BONE marrow cells
        Type: general
      – SubjectFull: ADULTS
        Type: general
      – SubjectFull: IRAQ
        Type: general
    Titles:
      – TitleFull: Prognostic significance of CD20 expression in Adults B-cell acute lymphoblastic leukemia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Adnan, Ban
      – PersonEntity:
          Name:
            NameFull: Sahham, Alaadin
      – PersonEntity:
          Name:
            NameFull: Alwan, Alaa Fadhil
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2023
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 18564550
          Numbering:
            – Type: volume
              Value: 18
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Revista Latinoamericana de Hipertensión
              Type: main
ResultId 1